Clinical Trials
4
Active:0
Completed:0
Trial Phases
3 Phases
Phase 2:1
Phase 4:1
Not Applicable:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Not Applicable
2 (50.0%)Phase 2
1 (25.0%)Phase 4
1 (25.0%)Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma
Phase 4
- Conditions
- Retroperitoneal Sarcoma
- Interventions
- Drug: Doxorubicin+Ifosfamide+Anlotinib(AI+A)Procedure: Radical Surgery
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Peking University International Hospital
- Target Recruit Count
- 102
- Registration Number
- NCT05844813
- Locations
- 🇨🇳
Beijing Friendship Hospital, Beijing, Beijing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
🇨🇳The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Study of Sirolimus in IgG4-related Disease
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Peking University International Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05746689
Study of Sirolimus in Idiopathic Retroperitoneal Fibrosis
- First Posted Date
- 2019-08-06
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Peking University International Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04047576
- Locations
- 🇨🇳
Peking University International Hospital, Beijing, Beijing, China
Precision Bypass in Patients With Moyamoya Disease
Not Applicable
Withdrawn
- Conditions
- Moyamoya Disease
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Peking University International Hospital
- Registration Number
- NCT03516851
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Peking University International Hospital, Beijing, Beijing, China
News
No news found